Astrazeneca Company Profile

What is the competitive landscape for ASTRAZENECA

ASTRAZENECA has ninety-two approved drugs.

There are ninety-five US patents protecting ASTRAZENECA drugs. There is one tentative approval on ASTRAZENECA drugs.

There are one thousand nine hundred and eighty-two patent family members on ASTRAZENECA drugs in sixty-five countries and three hundred and eighty-six supplementary protection certificates in twenty-one countries.

Summary for Astrazeneca

International Patents:	1982
US Patents:	95
Tradenames:	64
Ingredients:	60
NDAs:	92
Patent Litigation for Astrazeneca:	See patent lawsuits for Astrazeneca
PTAB Cases with Astrazeneca as patent owner:	See PTAB cases with Astrazeneca as patent owner

Drugs and US Patents for Astrazeneca

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-001	Nov 5, 2010		DISCN	Yes	No
Astrazeneca	PLENDIL	felodipine	TABLET, EXTENDED RELEASE;ORAL	019834-002	Jul 25, 1991		DISCN	Yes	No
Astrazeneca	XYLOCAINE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	010418-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-003	May 2, 2019		DISCN	Yes	No	6,515,117*PED				Y

Expired US Patents for Astrazeneca

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	9,198,925
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-002	Oct 20, 2006	4,853,230*PED
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-004	Dec 15, 2011	6,369,085*PED
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-001	Feb 20, 2001	5,690,960*PED
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,936,590

Paragraph IV (Patent) Challenges for ASTRAZENECA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	HydrochlorideExtended-release Tablets	2.5 mg/1000 mg		2018-10-29
	Nasal Spray	0.032 mg (32 mcg)/spray		2007-05-14
	Delayed-release for Oral Suspension	2.5 mg and 5 mg		2018-09-24
	Injection	50 mg/mL, 2.5 mL and 5 mL syringe		2009-10-01
	Inhalation Suspension	1 mg/2 mL		2010-05-28
	Delayed-release Tablets	20 mg		2012-03-30
	Tablets	60 mg		2015-09-30
	Tablets	500 mcg		2015-03-02
	Extended-release Tablets	5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg		2013-07-31
	Tablets	2.5 mg and 5 mg		2013-07-31
	Delayed-release	20 mg and 40 mg		2005-08-05
	For Injection	20 mg/vial and 40 mg/vial		2009-11-23
	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL		2005-09-15
	Delayed-release Capsules	20 mg		2007-03-19
	Tablets	90 mg		2015-07-20
	Tablets	5 mg, 10 mg, 20 mg and 40 mg		2007-08-13
	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe		2014-06-11

International Patents for Astrazeneca Drugs

Country	Patent Number	Estimated Expiration
China	105175396
Denmark	3689878
Iceland	8052
New Zealand	755117
European Patent Office	2498758

Supplementary Protection Certificates for Astrazeneca Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261586	SZ 4/2010	Austria		PRODUCT NAME: SAXAGLIPTIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND SAXAGLIPTINHYDROCHLORID
2822954	18C1035	France		PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625
0138504	2004C/004	Belgium		PRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1506211	300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astral
• Astrazeneca
• Astrazeneca Ab
• Astrazeneca Lp

AstraZeneca: Market Position, Strengths & Strategic Insights

Last updated: February 26, 2026

What is AstraZeneca’s current market position in the pharmaceutical industry?

AstraZeneca ranks among the top ten global pharmaceutical companies by revenue. In 2022, it achieved approximately $44 billion in sales, with major contributions from oncology (especially lung and breast cancer therapies), cardiovascular, renal, and metabolic diseases. The company holds leading positions in several therapeutic segments, notably in oncology, with a 13% global market share in this area, second only to Roche. Its geographic footprint extends globally, with the United States contributing roughly 44% of revenue, followed by Europe, Asia, and other regions.

What are AstraZeneca’s core strengths?

Portfolio Diversification

AstraZeneca’s portfolio spans multiple high-growth therapeutic areas. Its oncology segment, driven by blockbuster drugs like Tagrisso, Imfinzi, and Lynparza, accounts for nearly 50% of total sales. The company maintains a strong pipeline with over 80 projects progressing through clinical phases, emphasizing innovation in immuno-oncology, targeted therapies, and respiratory diseases.

R&D Investment

The company allocates approximately 20% of revenues to R&D, enabling continuous pipeline expansion. This level of investment exceeds industry averages and supports sustained innovation. Its R&D centers are located in key markets, including the UK, US, and Sweden.

Strategic Collaborations and Licensing

AstraZeneca has entered multiple partnerships, including co-development agreements with biotech firms and licensing deals with research institutes. These collaborations accelerate drug development and access to novel platforms such as antibody-drug conjugates and gene-based therapies.

Manufacturing Capabilities

The company has advanced manufacturing facilities globally, with significant capacity for biologics and small molecules. This supports reliable supply chains for commercial and clinical needs.

How does AstraZeneca compare with key competitors?

Company	2022 Revenue	Major Focus Areas	Pipeline Highlights	Market Share (Oncology)
Pfizer	$100B	Vaccines, oncology, cardiovascular	mRNA vaccines, cancer immunotherapies	8%
Roche	$63B	Oncology, diagnostics	Cancer immunotherapies, companion diagnostics	17%
Novartis	$51B	Oncology, biosimilars, ophthalmology	CAR-T therapies, biosimilars	9%
AstraZeneca	$44B	Oncology, CVRM, respiratory	PARP inhibitors, targeted lung therapies	13%

AstraZeneca outperforms many competitors in certain oncology niches, notably in targeted lung cancer treatments. Its focus on precision medicine has created a competitive advantage, though it faces stiff competition from Roche’s comprehensive oncology portfolio.

What strategic initiatives shape AstraZeneca’s future?

Focus on Oncology and Rare Diseases

AstraZeneca plans to expand its oncology pipeline, emphasizing personalized medicine. It has prioritized expanding the use of its landmark drugs and developing next-generation therapies for difficult-to-treat cancers.

Investment in Digital and Precision Medicine

The company is integrating digital health tools into clinical development and patient management. It collaborates with tech firms for data analytics, AI-driven drug discovery, and digital therapeutics.

Geographic Expansion

AstraZeneca is increasing market penetration in emerging markets, especially China and India, through tailored pricing strategies and local partnerships. It aims to roughly double revenues from emerging markets by 2025.

Sustainable Innovation and Pricing Strategies

AstraZeneca aligns its R&D and business models with sustainability initiatives, including responsible pricing and access programs to expand drug availability in lower-income regions.

What are the main risks and challenges?

• Patent expirations threaten revenue streams in mature segments.
• Competitive pressures intensify, especially from biologics and biosimilars.
• Regulatory challenges in novel therapies may delay market entry.
• Political and pricing pressures in key markets could affect profitability.

Closing Summary

AstraZeneca maintains strong positioning through diversification, a focused oncology pipeline, and strategic collaborations. Its aggressive R&D investment and expansion into emerging markets support growth despite competitive and regulatory risks.

Key Takeaways

• AstraZeneca is a top-10 global pharma company with a $44 billion revenue in 2022.
• Its oncology segment dominates, with a 13% market share and a pipeline of over 80 projects.
• The company’s strengths include diversified product lines, high R&D spending, strategic alliances, and manufacturing capacity.
• Competition from Roche, Pfizer, and Novartis remains intense, especially on innovative biologics.
• Future growth hinges on expanding oncology and rare disease portfolios, digital health integration, and geographic expansion in emerging markets.

Frequently Asked Questions

1. How does AstraZeneca’s pipeline compare to its competitors?

   • The company has over 80 projects in clinical stages, with significant investments in immuno-oncology, targeted therapies, and genetics-based treatments, positioning it strongly amid industry leaders.

2. What are the key drugs driving AstraZeneca’s current revenue?

   • Tagrisso, Imfinzi, Lynparza, and Farxiga are the main contributors, especially in oncology and cardiovascular/renal areas.

3. How is AstraZeneca addressing patent cliff risks?

   • Through pipeline expansion, lifecycle management of existing drugs, and diversification into rare diseases.

4. What geographies are critical for AstraZeneca’s growth?

   • The US remains dominant, but China and India are strategic for expansion, representing high-growth markets with localized strategies.

5. How does AstraZeneca invest in digital health?

   • It collaborates with tech companies to improve clinical trial efficiency, patient monitoring, and real-world data utilization, integrating AI and data analytics into its research processes.

---

References

[1] AstraZeneca Annual Report 2022. (2022). AstraZeneca.
[2] IQVIA. (2022). Top 20 Global Pharma Companies.
[3] Evaluate Pharma. (2022). World Preview 2022.
[4] Ross, J., & Zhang, Y. (2022). Competitive dynamics in global oncology. Pharma Intelligence.